Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Balanced discussion of second-generation antihistamines' data

Authors Boev R, Bentz JWG

Received 8 October 2016

Accepted for publication 27 October 2016

Published 24 November 2016 Volume 2016:12 Pages 1777—1781


Checked for plagiarism Yes

Editor who approved publication: Professor Garry Walsh

Rossen Boev,1 Jürgen WG Bentz2

1UCB Pharma, Bulle, Switzerland; 2UCB Pharma, Brussels, Belgium
It is with interest that we read the paper “Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine” by Wang et al1, in which the authors provide insights into the burden of allergic diseases in the Asia-Pacific region. Unfortunately, we found that the review provides some unsubstantiated information, incorrect statements, and/or data inconsistencies as listed below.
The abstract states that bilastine “has very low potential for drug–drug interactions”; however, the drug label lists interactions with ketoconazole, erythromycin, diltiazem, and other intestinal efflux transporters, leading to 2–3-fold increases in drug maximum serum concentration and area under the curve2. Also, food interactions decrease bilastine’s bioavailability by 30%, and the label recommendation is that it is taken 1 hour before or 2 hours after intake of food or fruit juice2
View the original article by Wang et al.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]